KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Co-Diagnostics (CODX) Share-based Compensation (2017 - 2025)

Historic Share-based Compensation for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to $500585.0.

  • Co-Diagnostics' Share-based Compensation fell 5212.38% to $500585.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year decrease of 4489.79%. This contributed to the annual value of $5.4 million for FY2024, which is 3480.87% down from last year.
  • Latest data reveals that Co-Diagnostics reported Share-based Compensation of $500585.0 as of Q3 2025, which was down 5212.38% from $580265.0 recorded in Q2 2025.
  • Over the past 5 years, Co-Diagnostics' Share-based Compensation peaked at $2.4 million during Q4 2022, and registered a low of $500585.0 during Q3 2025.
  • Moreover, its 5-year median value for Share-based Compensation was $1.5 million (2021), whereas its average is $1.5 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 24956.83% in 2021, then tumbled by 6130.68% in 2025.
  • Over the past 5 years, Co-Diagnostics' Share-based Compensation (Quarter) stood at $1.7 million in 2021, then soared by 45.01% to $2.4 million in 2022, then fell by 24.05% to $1.8 million in 2023, then decreased by 27.8% to $1.3 million in 2024, then crashed by 62.03% to $500585.0 in 2025.
  • Its Share-based Compensation was $500585.0 in Q3 2025, compared to $580265.0 in Q2 2025 and $875228.0 in Q1 2025.